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Angiogenesis is essential for normal and neoplastic tissue growth. In a recent issue of Nature,
Komuro and colleagues (Sano et al., 2007) describe how p53 expression in hypertrophying heart
muscle impairs HIF-1-mediated neovascularization and contributes to functional decompensation
of pressure-overload cardiac hypertrophy.The biological parallels between car-
diac hypertrophy and cancer are in-
tellectually stimulating and appear
increasingly relevant to the develop-
ment of novel therapeutics. In both
conditions, the underlying mecha-
nism is cell-type-specific growth that
exceeds normal physiological con-
straints. Abnormal growth in cardiac
hypertrophy emanates from cardiac
myocytes, which are limited in prolif-
erative potential and therefore grow
almost exclusively through cellular
hypertrophy (Olson and Schneider,
2003). Homotypic cellular growth in
cardiac hypertrophy and cancer cre-
ates an absolute requirement for neo-
vascularization to supply oxygen and
nutrients to the growing tissue. In tu-
mors, absence of macro- and micro-
vascularization results in tissue hyp-
oxia, development of a necrotic core,
and tumor involution. A similar necrotic
coremechanismhasbeenproposed at
the individual-myocyte level to explain
loss of cardiac myocytes and their
replacement by fibrosis during the
progression of compensated cardiac
hypertrophy to heart failure (Diwan
and Dorn, 2007).
Molecular events that stimulate neo-
vascularization in response to tissue
hypoxia have been elucidated in detail.
Hypoxia-inducible factor 1 (HIF-1),
which is unstable in normoxic cells, is
stabilized by hypoxia and acts as
a key transcriptional regulator of an-
giogenic factors, including vascular
endothelial growth factor (VEGF). Op-
posing HIF-1 is the p53 tumor sup-
pressor gene, encoding a transcrip-
tion factor that mediates the cellular
response to various injuries, including326 Cell Metabolism 5, May 2007 ª2007hypoxia. Under normal conditions,
p53 induces expression of proapop-
totic and antiangiogenic factors and
negatively regulates VEGF. Inactivat-
ing mutations of p53 are found in over
50% of human cancers, and HIF-1
is overexpressed in many cancers
(Levine, 1997; Zhong et al., 1999),
which promotes tumor neovascular-
ization and also likely facilitates tu-
mor progression and metastasis. Ravi
et al. (2000) were the first to define
the mechanistic link between p53 and
HIF-1 in tumor angiogenesis by show-
ing that p53 is required for ubiquitina-
tion and proteasomal degradation of
HIF-1a, and by demonstrating an in-
verse relationship between p53 levels
and HIF-1/VEGF expression and asso-
ciated neovascularization.
As tumor growth requires neovascu-
larization, so does myocardial growth.
Pressure overload, a potent stimulus
of pathological cardiac hypertrophy,
increases myocardial oxygen demand
while decreasing coronary perfusion
pressure and increasing extrinsic com-
pressive forces on the coronary mi-
crovasculature. Greater demand for
perfusion concomitant with increased
coronary resistance contributes to a
mismatch betweenmyocardial oxygen
demand and supply in hypertrophy
that presumably could beovercomeby
increasing the overall cross-sectional
area of the coronary microvascula-
ture, e.g., by neovascularization. In
the March 22, 2007 issue of Nature,
Komuro and colleagues (Sano et al.,
2007) report the discovery of a p53/
HIF-1 angiogenesis regulatory path-
way in cardiac hypertrophy similar to
that described in cancer.MicrosurgicalElsevier Inc.banding of the mouse transverse
aorta was used to create nonfailing
pressure-overload hypertrophy that
progressed to failing dilated cardiomy-
opathy. The authors observed a re-
quirement for myocardial neovascu-
larization in myocardial growth and
maintenance of normal function. They
further found that forced angiogenesis
by adenovirus-mediated expression of
VEGFand angiopoietin 1 enhancedhy-
pertrophy and preserved contractile
function after aortic banding. These
results support the idea that adequacy
of angiogenesis can be a critical de-
terminant of whether hypertrophy is
compensatory or is destined to fail.
This idea has support from studies
of Akt-induced myocardial growth by
Walsh and coworkers (Shiojima et al.,
2005),who found that conditional over-
expressionofAkt1 in cardiacmyocytes
initially enhanced cardiomyocyte
growth in parallel with neovasculariza-
tion and produced ‘‘physiological’’ hy-
pertrophy. However, when vasculari-
zation lagged behind hypertrophy,
cardiac function was compromised,
resulting in ‘‘pathological’’ hypertro-
phy. As in the Sano et al. study, forced
expression of angiogenic factors
downstream of Akt1 (including VEGF)
induced myocardial angiogenesis,
whereas VEGF blockade reduced cap-
illary density and accelerated the de-
velopment of heart failure.
The most exciting finding by Sano
et al. (2007) may be that the p53/
HIF-1 interaction impairs myocardial
angiogenesis during pressure-over-
load hypertrophy and thereby deter-
mines outcome. Using a combination
of genetic and pharmacological
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PreviewsFigure 1. Crosstalk between Positive and Negative Angiogenic Pathways in
Myocardial Hypertrophy
(Top) Physiological cardiac growth during postnatal development or with exercise conditioning is
stimulated by peptide growth factors that activate Akt via stimulation of tyrosine kinase growth-
factor receptors (GFR) and phosphatidylinositol 3-kinase (PI3K). Parallel activation of translational
and angiogenic pathways by Akt occurs viamammalian target of rapamycin (mTOR)-mediated ac-
tivation of ribosomal S6 kinase (S6K) and HIF-1 and by direct inhibition of antihypertrophic glyco-
gen synthase kinase 3 (GSK3). HIF-1 stimulates angiogenesis by inducing expression of multiple
angiogenic factors, including VEGF.
(Bottom) With stress, p53 is induced and destabilizes HIF-1 by promoting its ubiquitination and
degradation via the E3 ubiquitin protein ligase Mdm2. Core hypoxia of hypertrophied myocytes
also induces expression of REDD1, which inhibits mTOR and downstream angiogenic events.gain- and loss-of-function ap-
proaches, the authors show persua-
sively that downregulation of HIF-1a
by p53 expressed during the later
phase of hypertrophy contributes to
functional decompensation by de-
creasing expression of HIF-1-respon-
sive angiogenic factors. Consistent
with this mechanism, mice lacking p53
had a more robust hypertrophic re-
sponse and remained functionally
compensated after pressure overload.
Elucidation of a p53/HIF-1 angio-
genesis-modulating pathway in myo-
cardium does not diminish the im-
portance of other angiogenic events.
Indeed, coordinated regulation of car-
diomyocyte hypertrophy and myo-
cardial angiogenesis likely involves
complex signaling pathways and
crosstalk between cardiac myocytes
(the sensors of mechanical and meta-
bolic stress, elaborators of paracrine
factors, and engines for myocardial
contraction) and vascular endothelium
(the targets of elaborated angiogenic
factors and effectors of neovasculari-
zation). During normal heart develop-mental and exercise-induced phys-
iological hypertrophy, cardiomyocyte
growth and angiogenesis are stimu-
lated in parallel through the Akt/PI3K/
S6K pathway by peptide growth fac-
tors and their receptors (reviewed in
detail in Shiojima and Walsh, 2006).
Akt increases HIF-1 independent of
hypoxia via stimulation of mTOR,
providing for myocardial neovasculari-
zation without induction of a stress
response (Figure 1). However, when
myocardial work demands are in-
creased by hemodynamic overload or
myocardial injury, the stress response
includes stimulation of pathological
hypertrophy signaling through neuro-
hormone receptors (Dorn and Force,
2005), inhibition of mTOR by REDD1,
and enhanced degradation of HIF-1
through p53-mediated recruitment of
the E3 ubiquitin protein ligase Mdm2
(Shiojima and Walsh, 2006) (Figure 1).
Consequently, core hypoxia of hy-
pertrophied cardiomyocytes para-
doxically exaggerates the imbalance
between cardiomyocyte mass and
coronary microvasculature, producingCell Metaboa feed-forward downward metabolic
spiral that ultimately overwhelms the
myocytes’ ability to function (myocar-
dial hibernation) or remain viable (myo-
cyte dropout).
The Sano et al. (2007) paper raises
a number of intriguing questions. Is
there a primary role for p53-induced
cell-death genes in hypertrophy de-
compensation, or is apoptosis in this
condition largely secondary tomyocyte
hypoxia?Doother p53 targetsalso reg-
ulate the angiogenic response, such as
the early growth response 1 (Egr-1)
gene that physically interacts with p53
and coordinates expression of multiple
growth and angiogenic factors, includ-
ing the VEGF receptor Flt-1 (Khachi-
gian, 2006;Liu et al., 2001)? Is therepo-
tential utility in targeting themyocardial
p53/HIF-1 interaction to promote an-
giogenesis in acute or chronic myocar-
dial ischemia, or in combination with
myocardial regenerative therapies?
Answers to these questions await fur-
ther study. In the interim, the evidence
supports an approach of ‘‘feed the
heart, stave off failure.’’
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